Comparison of PathVysion and INFORM flourescence in situ hybridization kits for assessment of HER-2/neu stares in breast carcinoma

Molecular Diagnosis

Volumn 5, Issue 3, 2000, Pages 193-197

  Kakar, Sanjay ^a   Puangsuvan, Nick ^a   Stevens, Jane M ^a   Serenas, Romualda ^a   Mangan, George ^a   Sahai, Shalini ^a   Mihalov, Michael L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Immunohistochemistry; INFORM; PathVysion; Prognosis

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER GENETICS; CHROMOSOME 17; CLINICAL ARTICLE; DEVICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE TECHNOLOGY; HUMAN; MORPHOLOGY; ONCOGENE NEU;

EID: 0033792529     PISSN: 10848592     EISSN: None     Source Type: Journal    
DOI: 10.1054/modi.2000.16689     Document Type: Article

References (10)

1. Phase 2 study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with Her-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
2. Recombinant humanized anti-Her-2/neu antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against Her-2/neu overexpressing human breast cancer xenografts
3. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
4. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and Her-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer
5. Sensitivity of Her-2/neu antibodies in archival samples: Potential source of error in immunohistochemical studies of oncogene expression
6. Her-2/neu testing comes of age
7. Detection and quantitation of Her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
8. c-erb-b2 Overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis
9. Interphase cytogenetics in mammographically detected breast lesions
10. Incidence of chromosome 1 and 17 aneusomy in breast cancer and adjacent tissue: An interphase cytogenetic study